Top

Published in:

Open Access 01-12-2023 | Anaphylaxis | Case report

Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report

Published in: Journal of Medical Case Reports | Issue 1/2023

Abstract

Background

Bamlanivimab and etesevimab had been granted emergency use authorization in children under 12 years who are at risk of progression from mild/moderate coronavirus disease 2019 to severe disease and hospitalization.

Case report

We report on a 5-year-old white male with preexisting conditions, predisposing him to severe disease, who developed hypoxia and flushing 3 minutes into his infusion, thus meeting the criteria for anaphylaxis.

Conclusions

We believe this patient developed either an immunoglobulin E-mediated anaphylactic or a non-immunoglobulin E-mediated anaphylactoid reaction to bamlanivimab and etesevimab, which is an important possibility to consider on administration.

Fadavi P, Houshyari M, Yousefi Kashi AS, Jarrahi AM, Roshanmehr F, Broomand MA, Sandoughdaran S, Taghizadeh-Hesary F. Review on the oncology practice in the midst of COVID-19 crisis: the challenges and solutions. Asian Pac J Cancer Prev. 2021;22(1):19–24.CrossRefPubMedPubMedCentral

Rakhsha A, Azghandi S, Taghizadeh-Hesary F. COVID-19 pandemic and patients with cancer: the protocol of a Clinical Oncology Center in Tehran, Iran. Rep Pract Oncol Radiother. 2020;25(5):765–7.CrossRefPubMedPubMedCentral

Fact sheet for health care providers: emergency use authorization (EUA) of bamlanivimab and etesevimab. https://www.fda.gov/media/145802/download.

Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–44.CrossRefPubMedPubMedCentral

Eli Lilly and Company. A study of immune system proteins in participants with mild to moderate COVID-19 illness (BLAZE-4). In: https://clinicaltrials.gov; 2021.

Eli Lilly and Company. A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in participants with mild to moderate COVID-19 illness (BLAZE-1). In: https://clinicaltrials.gov; 2021.

Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, Perry R, Boscia J, Heller B, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385(15):1382–92.CrossRefPubMed

Nhean S, Varela ME, Nguyen YN, Juarez A, Huynh T, Udeh D, Tseng AL. COVID-19: a review of potential treatments (corticosteroids, remdesivir, tocilizumab, bamlanivimab/etesevimab, and casirivimab/imdevimab) and pharmacological considerations. J Pharm Pract. 2021. https://doi.org/10.1177/08971900211048139.CrossRefPubMed

Poowuttikul P, Seth D. Anaphylaxis in children and adolescents. Immunol Allergy Clin N Am. 2021;41(4):627–38.CrossRef

10.

Lagopoulos V, Gigi E. Anaphylactic and anaphylactoid reactions during the perioperative period. Hippokratia. 2011;15(2):138.PubMedPubMedCentral

11.

Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325–38.CrossRefPubMed

12.

Worm M, Hanschmann-Mohn T, Scherer Hofmeier K, Cardona V, Turner P, Dölle-Bierke S. Drug-induced anaphylaxis—elicitors, mechanisms and diagnosis. Allergo J Int. 2019;28(8):327–9.CrossRef

13.

Sobczak M, Pawliczak R. The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis. Clin Mol Allergy. 2022;20(1):1.CrossRefPubMedPubMedCentral

14.

Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14(2):E10-21.CrossRefPubMed

Title: Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report
Publication date: 01-12-2023
Keywords: Anaphylaxis
COVID-19
Anaphylaxis
Published in: Journal of Medical Case Reports / Issue 1/2023
Electronic ISSN: 1752-1947
DOI: https://doi.org/10.1186/s13256-023-03779-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report

Abstract

Background

Case report

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case report

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Transjugular intrahepatic portosystemic shunt-induced hemolysis in a non-cirrhotic patient: a case report

Elevation of cancer antigen 15-3 owing to oncocytic renal neoplasm in a patient without evidence of breast cancer recurrence on follow-up: a case report

Necrobiosis lipoidica of the breast associated with Crohn’s disease: a case report

Penile gangrene due to improper application of a condom catheter: a case report

Extremely elevated creatine kinase associated with rhabdomyolysis-induced acute kidney injury in a patient with Huntington’s disease: a case report

The association between acute brucellosis with a Guillain–Barré syndrome-like presentation: a case report